JPWO2023277166A1 - - Google Patents

Info

Publication number
JPWO2023277166A1
JPWO2023277166A1 JP2022566304A JP2022566304A JPWO2023277166A1 JP WO2023277166 A1 JPWO2023277166 A1 JP WO2023277166A1 JP 2022566304 A JP2022566304 A JP 2022566304A JP 2022566304 A JP2022566304 A JP 2022566304A JP WO2023277166 A1 JPWO2023277166 A1 JP WO2023277166A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022566304A
Other languages
Japanese (ja)
Other versions
JP7430946B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023277166A1 publication Critical patent/JPWO2023277166A1/ja
Priority to JP2024009621A priority Critical patent/JP2024046661A/ja
Application granted granted Critical
Publication of JP7430946B2 publication Critical patent/JP7430946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022566304A 2021-07-02 2022-06-30 クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物 Active JP7430946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024009621A JP2024046661A (ja) 2021-07-02 2024-01-25 クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021110423 2021-07-02
JP2021110423 2021-07-02
PCT/JP2022/026399 WO2023277166A1 (ja) 2021-07-02 2022-06-30 クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024009621A Division JP2024046661A (ja) 2021-07-02 2024-01-25 クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物

Publications (2)

Publication Number Publication Date
JPWO2023277166A1 true JPWO2023277166A1 (https=) 2023-01-05
JP7430946B2 JP7430946B2 (ja) 2024-02-14

Family

ID=84692754

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566304A Active JP7430946B2 (ja) 2021-07-02 2022-06-30 クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物
JP2024009621A Pending JP2024046661A (ja) 2021-07-02 2024-01-25 クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024009621A Pending JP2024046661A (ja) 2021-07-02 2024-01-25 クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物

Country Status (7)

Country Link
US (1) US20240417450A1 (https=)
EP (1) EP4364755A4 (https=)
JP (2) JP7430946B2 (https=)
KR (1) KR20240026998A (https=)
CN (1) CN117580590A (https=)
CA (1) CA3224499A1 (https=)
WO (1) WO2023277166A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240082370A (ko) * 2021-09-30 2024-06-10 이구아루판 가부시키가이샤 모노클로널 항체 함유 조성물
TW202440928A (zh) 2023-03-03 2024-10-16 國立大學法人東京大學 免疫球蛋白
CN121127591A (zh) * 2023-05-12 2025-12-12 国立大学法人东京大学 与艰难梭菌结合的抗体
WO2025220732A1 (ja) * 2024-04-17 2025-10-23 国立研究開発法人国立循環器病研究センター 肺高血圧症の予防又は治療薬

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020356A1 (en) * 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
WO2014142084A1 (ja) * 2013-03-11 2014-09-18 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法
US20160137724A1 (en) * 2011-08-02 2016-05-19 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
PT2411410E (pt) * 2009-03-27 2015-10-09 Gojo Ind Inc Composições e métodos para screening e utilização de compostos que antagonizam interações esporo-superfície
AR086199A1 (es) * 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
JP2017001987A (ja) * 2015-06-11 2017-01-05 学校法人関西文理総合学園 ポリペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020356A1 (en) * 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
US20160137724A1 (en) * 2011-08-02 2016-05-19 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
WO2014142084A1 (ja) * 2013-03-11 2014-09-18 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法

Also Published As

Publication number Publication date
KR20240026998A (ko) 2024-02-29
EP4364755A1 (en) 2024-05-08
CA3224499A1 (en) 2023-01-05
JP2024046661A (ja) 2024-04-03
US20240417450A1 (en) 2024-12-19
CN117580590A (zh) 2024-02-20
WO2023277166A1 (ja) 2023-01-05
JP7430946B2 (ja) 2024-02-14
EP4364755A4 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JPWO2023277142A1 (https=)
BR112022009896A2 (https=)
JPWO2023277166A1 (https=)
BR112021017747A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221028

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240125

R150 Certificate of patent or registration of utility model

Ref document number: 7430946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150